Ankara City Hospital

The trials here

What the 32 trials at this site are about, from their registry records.

Conditions

• Lung cancer8 trials
• Metastatic breast cancer7 trials
• Gastric and oesophageal cancer6 trials
• Bladder cancer2 trials
• Cervical cancer2 trials
• Melanoma2 trials
• Pancreatic cancer2 trials
• Stroke2 trials
• Aortic aneurysm1 trial
• Colorectal cancer1 trial
• Congenital heart disease1 trial
• Crohn's disease1 trial
• and 11 more

Phase

• Phase 311 trials
• Phase 25 trials
• Phase 1/24 trials
• Phase 12 trials
• Phase 2/31 trial

Status

• Active, not recruiting10 trials
• Completed10 trials
• Recruiting9 trials
• Not yet recruiting3 trials

Lead sponsor

• Hoffmann-La Roche9 trials
• BioNTech SE4 trials
• Ankara City Hospital Bilkent3 trials
• Ankara Yildirim Beyazıt University2 trials
• Daiichi Sankyo2 trials
• and 12 more

Running trials

• Recruiting

  A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS)

  NCT07282574· Phase 2· Hoffmann-La Roche· Source

• Not yet recruiting

  Renal Functions in Preeclamptic Pregnant Women Using Neutrophil Gelatinase-associated Lipocalin (NGAL) and Standard Renal Function Tests

  NCT07015359· Nihan Aydin Guzey· Source

  Contact: Ankara City Hospital

• Recruiting

  A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer

  NCT06892548· Phase 1/2· BioNTech SE· Source

• Recruiting

  A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer

  NCT06827236· Phase 1/2· BioNTech SE· Source

• Recruiting

  A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer

  NCT06790693· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer

  NCT06731478· Phase 3· Daiichi Sankyo· Source

• Recruiting

  An International Multicenter Study on Transcatheter Device Closure of Perimembranous Ventricular Septal Defects

  NCT06823635· Fondation Hôpital Saint-Joseph· Source

  Contact: Raymond N. Haddad, MD, MHSc, PhDc

• Active, not recruiting

  Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)

  NCT06635824· Phase 3· Genmab· Source

• Recruiting

  A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer

  NCT06532006· Phase 3· Shanghai Henlius Biotech· Source

  Contact: Ying Li

• Active, not recruiting

  Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With Chemotherapy

  NCT06449209· Phase 2· BioNTech SE· Source

• Recruiting

  Severe Complications During Ventricular Tachycardia or Premature Ventricular Complex Ablation

  NCT07777744· University Hospital, Basel, Switzerland· Source

  Contact: Serkan Cay

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)

  NCT06330064· Phase 1/2· Daiichi Sankyo· Source

  Contact: Principal Investigator

• Active, not recruiting

  A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)

  NCT06065748· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)

  NCT06095583· Phase 3· Shanghai Junshi Bioscience Co., Ltd.· Source

  Contact: Mehmet Sendur

• Active, not recruiting

  Ankura™ AAA, Cuff and AUI Stent Graft System Post-Market Clinical Follow-Up

  NCT05864560· Lifetech Scientific (Shenzhen) Co., Ltd.· Source

• Active, not recruiting

  A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)

  NCT05296798· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer

  NCT05142189· Phase 1· BioNTech SE· Source

• Active, not recruiting

  Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC

  NCT04821622· Phase 3· Pfizer· Source

• Active, not recruiting

  A Study Evaluating the Efficacy and Safety of Giredestrant Compared With Physician's Choice of Endocrine Monotherapy in Participants With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (acelERA Breast Cancer)

  NCT04576455· Phase 2· Hoffmann-La Roche· Source

• Active, not recruiting

  A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease

  NCT04232553· Phase 3· Eli Lilly and Company· Source

• Active, not recruiting

  Dose Escalation Study of a PD1-LAG3 Bispecific Antibody in Patients With Advanced and/or Metastatic Solid Tumors

  NCT04140500· Phase 1/2· Hoffmann-La Roche· Source

• Active, not recruiting

  TSR-042 as Maintenance Therapy for Patients With High-risk Locally Advanced Cervical Cancer After Chemo-radiation

  NCT03833479· Phase 2· Grupo Español de Investigación en Cáncer de Ovario· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Gastric and oesophageal cancer3 recruiting
• Lung cancer3 recruiting
• Metastatic breast cancer3 recruiting
• Bladder cancer1 recruiting
• Cervical cancer1 recruiting
• Colorectal cancer1 recruiting
• Congenital heart disease1 recruiting
• Endometrial cancer1 recruiting
• Head and neck cancer1 recruiting
• Liver and biliary tract cancer1 recruiting
• Melanoma1 recruiting
• Multiple sclerosis1 recruiting
• Ovarian cancer1 recruiting
• Pancreatic cancer1 recruiting
• Ventricular tachycardia1 recruiting

Closed trials

• Completed

  Comparison of Fentanyl and Magnesium to Control Reflex Hemodynamics in Patients Aged 50 and Older

  NCT07258628· Ankara City Hospital Bilkent· Source

• Completed

  Aerobic Training and Cardiopulmonary Responses In Heart Failure

  NCT07128784· Ankara City Hospital Bilkent· Source

• Completed

  Virtual Reality Based Robotic Gait and Balance Trainer

  NCT06164197· Ankara Yildirim Beyazıt University· Source

• Completed

  A Study to Evaluate Safety, Pharmacokinetics, & Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors; Urothelial Carcinoma Substudy in Association With RO7496353 Study GO44010

  NCT05867121· Phase 1· Genentech, Inc.· Source

• Completed

  "Potential Effects of Virtual Reality Technology on the Treatment of Migraine-Type Headaches"

  NCT06061588· Ankara City Hospital Bilkent· Source

• Completed

  The Effects of Balance Trainer

  NCT06166004· Ankara Yildirim Beyazıt University· Source

• Completed

  A Study of Tobemstomig Plus Platinum-Based Chemotherapy vs Pembrolizumab Plus Platinum-Based Chemotherapy in Participants With Previously Untreated Non-Small Cell Lung Cancer

  NCT05775289· Phase 2· Hoffmann-La Roche· Source

• Completed

  A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy.

  NCT05523167· Phase 2/3· argenx· Source

• Completed

  A Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration in Participants With Early or Locally Advanced/Inflammatory HER2-Positive Breast Cancer

  NCT05415215· Phase 3· Hoffmann-La Roche· Source

• Completed

  A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy

  NCT04543617· Phase 3· Hoffmann-La Roche· Source